Aportación de la farmacocinética al tratamiento con fenobarbitalaplicación a algunos casos clínicos

  1. García Sánchez, M.ª José 1
  2. Vivar Pérez, Marina 1
  3. Santos Buelga, M.ª Dolores 1
  1. 1 Universidad de Salamanca
    info

    Universidad de Salamanca

    Salamanca, España

    ROR https://ror.org/02f40zc51

Journal:
Farmajournal

ISSN: 2445-1355

Year of publication: 2022

Volume: 7

Issue: 1

Pages: 83-91

Type: Article

DOI: 10.14201/FJ2022718391 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Farmajournal

Abstract

The aim of the study is to evaluate the predictive capacity of a pharmacokinetic population model of phenobarbital developed in the Faculty of Pharmacy in the University of Salamanca and implemented in a Clinical Pharmacokinetics software under development (WinPKs). This software enables the estimation of pharmacokinetic parameters in monitored patients diagnosed with epilepsy. For this purpose, Bayesian algorithms are applied requiring both a priori information on the plasma concentration of the drug in each patient and data from the population model implemented by the software. The study was conducted in 30 outpatients aged 19-87 years, who belonged to the therapeutic monitoring programme of the Pharmacy Department in Hospital Clínico Universitario de Salamanca. A total of 79 phenobarbital plasma concentrations obtained at the end of the dosing interval and at equilibrium were available. To assess the predictive capacity of the population model, prediction errors between predicted and observed concentrations were calculated, with a mean error of less than 2?%. Even though the results of the study confirm the suitability of the phenobarbital population model, a larger sample size would be required to conclude its usefulness in optimising drug dosing regimens.

Bibliographic References

  • Agencia Española de Medicamentos y Productos Sanitarios. Centro de Información online de medicamentos. CIMA AEMPS [Internet]. Ficha técnica Gardenal [revisado jun. 2021]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/49002/49002_ft.pdf.Agencia Española de Medicamentos y Productos Sanitarios. Centro de Información online de medicamentos. CIMA AEMPS [Internet]. Ficha técnica Luminal [revisado jun. 2021]. Disponible en: https://cima.aemps.es/cima/pdfs/es/ft/3905/3905_ft.pdf.
  • André P et al. Therapeutic drug monitoring of antiepileptic drugs in 21st century. Epileptologie. 2015; 32:78-84.
  • Domenech J, Martínez Lanao J et al. Tratado General de Biofarmacia y Farmacocinética. Volumen II: Vías de administración de fármacos: aspectos biofarmacéuticos. Farmacocinética no lineal y clínica. Madrid: Síntesis; 2013. p. 243-363.
  • Escobar L. Monitorización terapéutica de fármacos y aspectos prácticos de farmacocinética. Rev Med Clin Codes. 2016; 27(5):605-614.
  • García Sánchez MJ, Martín Suárez A. Metodología de la monitorización. En: Domínguez-Gil Hurlé A, coordinador. Monitorización de fármacos en la práctica clínica. Universidad de Salamanca (Facultad de Farmacia); 2015. p. 37-59.
  • Neels HM, Sierens AC et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med. 2004; 42(11):1228-1255.
  • Teixeria-da-Silva P, Santos-Buelga D et al. Population Pharmacokinetics of phenobarbital in Caucasian patients with epilepsy. European Journal of Pharmaceutical Sciences. 2020; 153:928-987.
  • Varona J, Escribano E et al. Fenobarbital: farmacocinética, toxicología y monitorización por el Laboratorio. Rev Diagn Biol [revista en Internet]. 2001 [acceso 20 de mayo de 2021]; 150(1). Disponible en https://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0034-79732001000100002.
Data source: Dialnet